Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    LongevityPreclinical

    NMN Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about NMN dosing — protocols, safety, and where to buy.

    Dosage Calculator

    Calculate exact dosing for NMN.

    Dosing Protocols

    Beginner

    For individuals starting NMN for longevity, metabolic health, or energy support, the standard beginner protocol is: Start with 250 mg oral NMN once daily taken in the morning with water. The morning timing supports the circadian-NAD+ peak and avoids theoretical sleep disruption from NAD+-mediated alertness. Take on an empty stomach or with a light meal for theoretical absorption advantages, though the evidence for fasting-versus-fed dosing is limited. Continue at 250 mg/day for 4-8 weeks while assessing tolerance (GI effects, sleep quality, energy levels) and any measurable outcomes (if tracking biomarkers). This dose approximates the Yoshino 2021 trial dose and is a reasonable entry point for most users. If tolerated well and pursuing higher NAD+ support, increase to 500 mg/day (taken as single morning dose or split 250 mg BID morning and midday). This dose approaches the Liao 2021 running trial middle dose. Monitor baseline and follow-up measures if feasible: fasting glucose, HbA1c, blood pressure, body composition, subjective energy/sleep/cognition. Some practitioners recommend periodic NAD+ testing (jaded by widely variable results between assays) to confirm elevation — this is not strictly necessary but can inform dosing decisions. Quality selection: choose reputable brands (Uthever / Renue / DoNotAge / ProHealth / Thorne etc.) with third-party testing certificates. Store NMN in a cool dry place or refrigerate for longer shelf-life. Expect to purchase capsules or sublingual powder; both are acceptable with capsules more convenient and sublingual theoretically offering enhanced bioavailability (though unconfirmed in controlled studies). Avoid extremely cheap NMN from unknown sources — independent testing has documented substantial under-labeling in budget products.

    Standard

    For intermediate users established on NMN, several optimization strategies apply. Dose optimization: 500-1,000 mg/day is the common intermediate dose range, split BID or taken as a single morning dose. The Pencina 2023dose-ranging study supports safety up to 900 mg/day for short-term use. Above 1,000 mg/day additional benefit is not documented and diminishing returns likely given saturation of NAD+ biosynthetic capacity. Timing: morning dose supports circadian alignment; avoid evening dose for most users. If split BID, morning and midday are preferred. Route of administration: oral capsules are standard. Sublingual powder is popular based on theoretical buccal absorption bypassing intestinal degradation, though controlled evidence that sublingual substantially outperforms oral is limited. Intranasal NMN products are available from some vendors; evidence for substantial superiority over oral is minimal. Injectable NMN is available from compounding pharmacies and research chemical vendors; the pharmacokinetic advantage is real (bypasses intestinal absorption entirely) but clinical outcomes data is absent and the practical considerations (injection skill, sterility, cost) limit adoption. Cycling: some practitioners recommend periodic cycling (6 weeks on, 2 weeks off) based on theoretical concerns about receptor desensitization or methyl depletion; no controlled evidence supports this pattern over continuous use. Continuous NMN in preclinical rodent studies has not produced attenuating effects. Combinations: consider adding B-vitamin complex (folate, B12, B6) or TMG 500-1,000 mg/day for methylation support if pursuing higher NAD+ precursor doses. Stack with metformin, resveratrol, or other evidence-based longevity agents per individual profile and informed consent. Monitoring: annual metabolic panel, HbA1c, complete blood count, lipid panel. Periodic (every 6-12 months) assessment of function/energy/sleep/cognition to inform ongoing risk-benefit. Duration: continuous use over months to years is typical; evidence for harm accumulates is not present but long-term safety database is limited. Periodic reassessment of rationale and evidence base is reasonable.

    Advanced

    Advanced NMN protocols are investigational and should be approached with informed skepticism about the uncertainty of incremental benefit. High-dose NMN (1,000-2,000 mg/day): Some advanced users have pursued doses above the Yoshino/Liao/Pencina trial ranges. No evidence supports meaningful additional benefit above 1,000 mg/day, and methyl depletion and other theoretical concerns become more salient at high doses. Subcutaneous or IV NMN: Provides direct systemic NAD+ precursor delivery bypassing intestinal absorption. Reasonable PK rationale; clinical outcomes data absent. Requires sterile injection technique and compounded product (not commercial-supplement available). NMN + senolytic integration: Quarterly fisetin (1,500 mg/day × 2 days) or dasatinib-quercetin cycles combined with chronic NMN. Conceptually sound; investigational. NMN + rapamycin (sirolimus): Chronic NMN 500-1,000 mg/day combined with weekly rapamycin 5-7 mg creates the "Attia longevity pharmaceutical stack" when combined with metformin. See /compound/rapamycin when available. Evidence base is mechanistic and observational; no RCT data on combined use. NMN + epigenetic reprogramming approaches: Experimental combination with OSK (Oct4/Sox2/Klf4) factors or yamanaka factor-adjacent compounds. Investigational and research-stage. NMN + comprehensive aging biomarker tracking: Some advanced users track GrimAge, PhenoAge, DunedinPACE, or other epigenetic clocks to assess longevity intervention impact. Evidence that NMN alters these clocks is mixed (some studies show small improvements, others null). Multi-year high-dose NMN: Continuous high-dose NMN for 5+ years has no published safety or efficacy data in humans. Preclinical rodent data at equivalent exposure has not revealed adverse effects. Uncertainty is substantial. Combination with specific peptides: Combinations with thymosin alpha 1, BPC-157, NAD+ direct injection, or others have been pursued. Evidence is preclinical or anecdotal for combined use. Advanced users integrating NMN into comprehensive healthspan protocols should have documented rationale, track outcomes, and accept the preliminary state of evidence for any novel combination. Professional physician supervision is appropriate for multi-agent advanced protocols given the prescription agents often involved.

    Commonly Stacked With

    NMN is commonly combined with other longevity-oriented compounds based on mechanistic rationale, though controlled evidence for combined use is largely absent. NMN + metformin: Both target metabolic/aging pathways through complementary mechanisms — NMN elevates NAD+, metformin activates AMPK and inhibits complex I. Sinclair and others have proposed this combination as a foundational longevity stack. No controlled human trials have tested the combination. Safety appears good based on individual agent profiles. Practical considerations: consider the Konopka 2019 metformin-exercise attenuation finding in individuals prioritizing fitness training. NMN + rapamycin (when available): Combines mTOR inhibition (rapamycin) with NAD+/sirtuin activation (NMN). Rapamycin's weekly pulsed dosing (5-7 mg/week) with chronic NMN is a popular longevity-focused combination. Uncontrolled in human trials. NMN + resveratrol: The original Sinclair-era stack combining sirtuin cofactor (NAD+ from NMN) with sirtuin activator (resveratrol). Resveratrol's sirtuin-activating effects have been contested and likely involve more complex mechanisms than direct sirtuin activation. The combination is rational on Sinclair's mechanistic framework but marginally evidence-supported in humans. NMN + trans-pterostilbene: Similar logic to resveratrol; often combined in commercial longevity stacks. NMN + spermidine: Spermidine induces autophagy; combined with NMN provides autophagy induction plus NAD+ support. Preclinical evidence for combined benefit; human evidence limited. NMN + NAD+ precursor rotation: Some practitioners rotate or combine NMN with nicotinamide riboside (NR) or nicotinic acid based on theoretical pathway-coverage considerations. No controlled evidence supports rotation over monotherapy. NMN + sulforaphane (from broccoli sprout extract): Sulforaphane activates Nrf2 antioxidant response; NMN supports NAD+/sirtuin pathways. Rational complementary mechanisms. NMN + TMG (trimethylglycine/betaine) or B-vitamins for methylation support: Addresses theoretical methyl depletion concern from high-dose NAD+ precursors. TMG at 500-1,000 mg/day or standard B-complex with folate, B12, and B6. Evidence for practical importance in healthy adults at typical NMN doses is limited but the safety/cost of adding methyl support is favorable. NMN + caloric restriction or intermittent fasting: Both activate similar nutrient-sensing pathways (sirtuins, AMPK, autophagy). Mechanistically redundant but not contraindicated. May have additive effects in animal models. NMN + exercise training: Unlike metformin, NMN does not appear to attenuate exercise adaptations. Liao et al. 2021 actually documented enhanced aerobic capacity with NMN in recreational runners. This distinguishes NMN from metformin for exercise-prioritizing individuals. NMN + GHK-Cu and other regenerative peptides: Mechanistically complementary (NAD+ supports cellular function; GHK-Cu promotes tissue regeneration). No controlled combined-use evidence but safety appears good. NMN + senolytics (fisetin, dasatinib-quercetin): Rational combination (periodic senescent cell clearance plus chronic metabolic support). Each class operates on different aging hallmarks; no combined trials. Avoid combining NMN with: alpha-lipoic acid supplementation at high doses during active NMN use may theoretically affect NAD+/NADH redox balance; evidence is minimal but conservative approach is to separate high-dose ALA and NMN timing. Active chemotherapy — NAD+ precursor use during chemotherapy should be discussed with oncology (potential interference with some cancer-directed metabolic therapies). Pharmaceutical stack alternatives: For individuals seeking formal longevity-directed pharmaceutical approaches, metformin remains the most evidence-supported single agent with the Bannister 2014 observational data and the TAME trial framework. SGLT2 inhibitors have emerging interest for healthy-aging applications. GLP-1 agonists (semaglutide, tirzepatide) have profound metabolic effects with cardiovascular and possibly cognitive benefits. These evidence-based interventions are more substantive than supplements for individuals willing to pursue pharmaceutical management.

    Side Effects & Safety

    NMN has a favorable short-term safety profile across tested human doses (100-1200 mg/day for up to 12 weeks in available studies). Across multiple clinical trials, no serious NMN-attributable adverse events have been reported, and commonly-reported side effects are mild, transient, and similar to placebo rates. Specific adverse effects reported in human trials: GI effects — mild nausea, stomach discomfort, or loose stools in approximately 5-10% of users, typically resolving with continued use or dose reduction. Taking NMN with food may reduce GI effects. Flushing — mild facial flushing is uncommon with NMN (less than with high-dose nicotinamide or niacin). Headache — occasional mild headaches reported. Fatigue or drowsiness — rare, typically mild. Insomnia — some users report mild insomnia with evening dosing, possibly due to NAD+-mediated circadian effects. Morning dosing avoids this. Irritability, agitation, or mood changes — rare and typically mild. Rare and uncertain potential adverse effects: Methyl group depletion — the NAD+ pathway ultimately metabolizes nicotinamide through methylation (via NNMT, which is interesting because inhibitors of NNMT like 5-amino-1MQ have been developed for their own geroprotective rationale). High-dose NAD+ precursor supplementation could theoretically deplete SAM-e methyl donor pools with consequences for DNA methylation, catecholamine synthesis, and other methyl-dependent processes. Clinical evidence for this risk in humans at typical NMN doses is minimal. Some practitioners recommend concurrent B-vitamin supplementation (folate, B12, B6) to support methylation capacity. Cancer concerns — a theoretical concern has been raised that elevated NAD+ could provide substrate for tumor cell proliferation. Animal studies have shown both pro- and anti-cancer effects of NAD+ precursors depending on tumor type and context. In humans, no signal of increased cancer incidence has been seen in available NMN trials, though the short duration of trials limits the ability to detect any such signal. For individuals with active cancer, NMN supplementation is not recommended without oncology consultation. Cardiovascular concerns — elevated NAD+ and sirtuin activation have mixed effects on cardiovascular outcomes in preclinical models. Human cardiovascular evidence suggests NMN/NR are neutral-to-favorable. Individuals with significant cardiovascular disease should discuss NMN use with their cardiologist. Drug interactions: NMN does not have significant documented drug interactions because it enters endogenous metabolic pathways. However, theoretical interactions include: (1) metformin — NMN and metformin may have overlapping metabolic effects (both influence AMPK and NAD+ pathways); concurrent use appears safe but is uncontrolled; (2) resveratrol — often co-marketed with NMN based on Sinclair's research combining sirtuin cofactor (NAD+) with sirtuin activator (resveratrol); safety appears good; (3) niacin (nicotinic acid) and niacinamide — competing NAD+ precursors; dose adjustment may be considered; (4) chemotherapy — see cancer concerns; discuss with oncology; (5) immunosuppressants — theoretical interactions via immune cell metabolism modulation; limited clinical evidence. Long-term safety: NMN human trials have generally been short-term (typically 6-12 weeks). Long-term (>1 year) NMN safety in humans is not established. Preclinical long-term NMN administration in mice (up to 12 months at high doses) has not produced adverse effects but extrapolation to humans over decades is uncertain. Special populations: Pregnancy and breastfeeding — no safety data; avoid. Pediatric — not studied; avoid outside specific clinical contexts. Elderly — primary target population; good short-term safety. Active cancer — avoid without oncology consultation. Chronic kidney disease — theoretical concerns about impaired NAD+ clearance; limited data. Hepatic impairment — limited data; caution. Formulation and quality concerns: Commercial NMN products vary substantially in purity, stability, and actual content versus label claim. Independent testing by ConsumerLab and others has documented wide variability. Unstable NMN degrades to nicotinamide and other products. Quality considerations: reputable brands with third-party testing (Uthever, Renue, DoNotAge, ProHealth are commonly-cited brands with reasonable quality control); powder forms generally fresher than tablets; storage at refrigerated or frozen temperatures preserves NMN integrity. Overall, NMN's short-term safety profile is strong but the long-term safety database is limited, and informed users should recognize this when considering multi-year supplementation.

    Contraindications

    NMN has a favorable short-term safety profile but specific populations warrant caution or avoidance. Absolute contraindications: Active cancer (avoid without oncology consultation — theoretical concerns about NAD+ as tumor substrate, though evidence is mixed); known hypersensitivity to NMN or related nucleotides. Relative contraindications (use with caution and specific monitoring): Pregnancy and breastfeeding — no safety data; avoid except in specifically authorized research contexts. Pediatric age — not studied; avoid outside specific clinical research. Chronic kidney disease stage 4-5 — theoretical concerns about impaired nucleotide clearance; limited data. Severe hepatic impairment — limited data; caution. Active chemotherapy or radiation therapy — discuss with oncology before concurrent use. Niacin flushing disorders — theoretical cross-reactivity concerns though rare. Immunosuppressive medication use — limited data on interactions. Specific medication interaction considerations: Chemotherapy with alkylating agents, platinum compounds, or topoisomerase inhibitors — theoretical interactions via DNA repair modulation (PARP substrate provision); discuss with oncology. Methotrexate and other methyl-dependent medications — theoretical methyl pool effects; limited clinical significance. Immunosuppressants — limited interaction data. Specific clinical situations: New unexplained weight gain, new GI symptoms, unexplained fatigue, abnormal lab findings during NMN use warrant discontinuation and evaluation. Persistent insomnia or mood changes warrant timing adjustment or discontinuation. Development of new cardiovascular symptoms warrants evaluation. Monitoring: Baseline metabolic panel, HbA1c, lipid panel, complete blood count before starting NMN at higher doses (>500 mg/day) is prudent. Annual monitoring during chronic use. Blood pressure monitoring during initial 4-8 weeks. Specific biomarker tracking (NAD+ levels, epigenetic clocks, inflammatory markers) is optional and research-adjacent. Practical considerations for surgical, diagnostic, or medical procedures: NMN can generally be continued during outpatient procedures. For major surgery, 1-week hold is conservative practice without strong evidence-base. No specific monitoring required beyond standard pre-operative labs. Emergency considerations: NMN overdose has not been reported. In theory, very high doses (>5,000 mg) might produce nausea, GI upset, and transient metabolic effects but would be expected to resolve quickly given the rapid nicotinamide metabolism. Symptoms requiring emergency evaluation are unlikely from NMN alone but could reflect underlying conditions worth evaluating. Quality-control considerations: Substandard NMN products (insufficient actual NMN, contamination, degradation products) are a meaningful practical concern. Use reputable brands with third-party testing. Avoid extremely cheap or unknown-source products. Store appropriately and discard expired products.

    Check interactions with the Interaction Checker →

    Additional Notes

    NMN dose selection is based on a combination of clinical trial doses, pharmacokinetic rationale, and practical considerations. Standard dose range: 250-1,000 mg/day for most users. 250 mg/day (Yoshino 2021 trial dose) is the entry-level dose with documented metabolic benefits. 500 mg/day is a common intermediate dose supported by several clinical trials. 1,000 mg/day approaches the maximum short-term tested dose. Timing: Morning dose preferred; split BID (morning + midday) if pursuing higher doses. Avoid evening/nighttime dosing to preserve sleep quality for most users. Take with water; food is optional and PK evidence is limited on fasted versus fed dosing. Formulations: Capsules (most common; typically 125, 250, or 500 mg per capsule); sublingual powder (popular for theoretical buccal absorption); tablets (less preferred due to compression effects on stability); liposomal formulations (marketed for enhanced absorption; evidence limited). Quality: Third-party tested products from reputable vendors preferred. Independent testing by ConsumerLab, Labdoor, or similar organizations has documented variability. Brands with good track records include Uthever/Renue/DoNotAge/ProHealth/Thorne/Jarrow Formulas. Budget brands often under-label (product contains less NMN than stated). Storage: Room temperature in sealed container is acceptable for short-term use. Refrigerated storage extends shelf-life. Frozen storage preferred for long-term storage (>6 months). NMN degrades over time; older product is less potent. Pharmacokinetic considerations: Single dose kinetics — peak plasma NMN at 15-30 minutes; peak plasma nicotinamide (major metabolite) at 30-60 minutes; intracellular NAD+ elevation develops over hours-to-days. Steady-state dosing produces sustained NAD+ elevation. Twice-daily dosing provides more stable exposure than once-daily. Injectable NMN (compounded): 100-300 mg SC or IV daily or several times weekly has been used in research and some clinical contexts. Bypasses intestinal absorption. Not commercial-supplement available; requires compounding pharmacy and injection skill. Sublingual / intranasal: Popular formulation claim but controlled evidence supporting superior absorption is limited. Practical consideration: 250-500 mg sublingual under the tongue for 1-2 minutes. Dose titration: Start at 250 mg/day; increase to 500 mg/day after 4-8 weeks if tolerated and pursuing higher NAD+ support; consider 1,000 mg/day after additional 4-8 weeks in specific use cases. Maximum recommended: 1,000-2,000 mg/day. Above this evidence and benefit are limited. Skip-dose cycling: Not evidence-supported; continuous use is acceptable. Combination with other NAD+ precursors: If using NR concurrently, total NAD+ precursor intake from NMN + NR should generally remain below 2,000 mg/day total.

    Frequently Asked Questions

    What is the recommended NMN dosage?

    Dosage for NMN varies by protocol. Consult a qualified healthcare provider.

    How often should I take NMN?

    Administration frequency depends on the specific protocol. Consult current research literature.

    Does NMN need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are NMN side effects?

    NMN has a favorable short-term safety profile across tested human doses (100-1200 mg/day for up to 12 weeks in available studies). Across multiple clinical trials, no serious NMN-attributable adverse events have been reported, and commonly-reported side effects are mild, transient, and similar to placebo rates. Specific adverse effects reported in human trials: GI effects — mild nausea, stomach discomfort, or loose stools in approximately 5-10% of users, typically resolving with continued use or dose reduction. Taking NMN with food may reduce GI effects. Flushing — mild facial flushing is uncommon with NMN (less than with high-dose nicotinamide or niacin). Headache — occasional mild headaches reported. Fatigue or drowsiness — rare, typically mild. Insomnia — some users report mild insomnia with evening dosing, possibly due to NAD+-mediated circadian effects. Morning dosing avoids this. Irritability, agitation, or mood changes — rare and typically mild. Rare and uncertain potential adverse effects: Methyl group depletion — the NAD+ pathway ultimately metabolizes nicotinamide through methylation (via NNMT, which is interesting because inhibitors of NNMT like 5-amino-1MQ have been developed for their own geroprotective rationale). High-dose NAD+ precursor supplementation could theoretically deplete SAM-e methyl donor pools with consequences for DNA methylation, catecholamine synthesis, and other methyl-dependent processes. Clinical evidence for this risk in humans at typical NMN doses is minimal. Some practitioners recommend concurrent B-vitamin supplementation (folate, B12, B6) to support methylation capacity. Cancer concerns — a theoretical concern has been raised that elevated NAD+ could provide substrate for tumor cell proliferation. Animal studies have shown both pro- and anti-cancer effects of NAD+ precursors depending on tumor type and context. In humans, no signal of increased cancer incidence has been seen in available NMN trials, though the short duration of trials limits the ability to detect any such signal. For individuals with active cancer, NMN supplementation is not recommended without oncology consultation. Cardiovascular concerns — elevated NAD+ and sirtuin activation have mixed effects on cardiovascular outcomes in preclinical models. Human cardiovascular evidence suggests NMN/NR are neutral-to-favorable. Individuals with significant cardiovascular disease should discuss NMN use with their cardiologist. Drug interactions: NMN does not have significant documented drug interactions because it enters endogenous metabolic pathways. However, theoretical interactions include: (1) metformin — NMN and metformin may have overlapping metabolic effects (both influence AMPK and NAD+ pathways); concurrent use appears safe but is uncontrolled; (2) resveratrol — often co-marketed with NMN based on Sinclair's research combining sirtuin cofactor (NAD+) with sirtuin activator (resveratrol); safety appears good; (3) niacin (nicotinic acid) and niacinamide — competing NAD+ precursors; dose adjustment may be considered; (4) chemotherapy — see cancer concerns; discuss with oncology; (5) immunosuppressants — theoretical interactions via immune cell metabolism modulation; limited clinical evidence. Long-term safety: NMN human trials have generally been short-term (typically 6-12 weeks). Long-term (>1 year) NMN safety in humans is not established. Preclinical long-term NMN administration in mice (up to 12 months at high doses) has not produced adverse effects but extrapolation to humans over decades is uncertain. Special populations: Pregnancy and breastfeeding — no safety data; avoid. Pediatric — not studied; avoid outside specific clinical contexts. Elderly — primary target population; good short-term safety. Active cancer — avoid without oncology consultation. Chronic kidney disease — theoretical concerns about impaired NAD+ clearance; limited data. Hepatic impairment — limited data; caution. Formulation and quality concerns: Commercial NMN products vary substantially in purity, stability, and actual content versus label claim. Independent testing by ConsumerLab and others has documented wide variability. Unstable NMN degrades to nicotinamide and other products. Quality considerations: reputable brands with third-party testing (Uthever, Renue, DoNotAge, ProHealth are commonly-cited brands with reasonable quality control); powder forms generally fresher than tablets; storage at refrigerated or frozen temperatures preserves NMN integrity. Overall, NMN's short-term safety profile is strong but the long-term safety database is limited, and informed users should recognize this when considering multi-year supplementation.

    Where can I buy NMN?

    Visit our vendor directory to find trusted sources for NMN.

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free
    ResearchChemHQ BPC-157 500mcg × 60 capsules bottle
    IN STOCK · COA PER BATCH

    BPC-157 Caps

    60 caps × 500mcg. HPLC + COA on every batch, ≥99% purity. Same molecule as the vials, just oral so it travels. code REDDIT stacks with their 5-vial 20% off and 10-vial 40% off tiers.

    COUPON CODEREDDIT
    Grab a bottle →
    Research use only. Not for human consumption.|BodyHackGuide promotes vendors. We do not sell these products.